Leerink Partners starts BlossomHill Therapeutics at Outperform, $36 target
Leerink Partners initiated coverage on BlossomHill Therapeutics with an Outperform rating and announced a $36.00/share price target.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.